Abstract: Genetic model organisms have the potential of removing blind spots from the underlying gene regulatory networks of human diseases. Allowing analyses under experimental conditions they complement the insights gained from observational data. An inevitable requirement for a successful trans-species transfer is an abstract but precise high-level characterization of experimental findings. In this work, we provide a large-scale analysis of seven weak contractility/heart failure genotypes of the model organism zebrafish which all share a weak contractility phenotype. In supervised classification experiments, we screen for discriminative patterns that distinguish between observable phenotypes (homozygous mutant individuals) as well as wild-type (homozygous wild-types) and carriers (heterozygous individuals). As the method of choice we use semantic multi-classifier systems, a knowledge-based approach which constructs hypotheses from a predefined vocabulary of high-level terms (e.g., Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways or Gene Ontology (GO) terms). Evaluating these models leads to a compact description of the underlying processes and guides the screening for new molecular markers of heart failure. Furthermore, we were able to independently corroborate the identified processes in Wistar rats.

Keywords: Heart failure phenotypes; zebrafish; Wistar rat; semantic multi-classifier systems

1. Introduction

Human heart failure (HF) is the leading cause of hospitalization in Western world countries and is associated with high morbidity and mortality thereby putting a large burden on health care costs [1]. Alarmingly, over the last decade, heart failure incidence further increased with a rate of about 1% per year mostly attributed to demographic changes and an aging population [2]. However, up to now, the molecular underpinnings of HF are still only poorly defined but are essential for the development and the clinical implementation of targeted and tailored HF therapies. In this context, the use of established model organisms such as mice and zebrafish to model human heart failure now enable the systematic dissection and definition of the molecular etiology of HF. In recent years, we analyzed several zebrafish lines suffering from heart failure which were identified in large-scale zebrafish
forward genetics mutagenesis screens [3]. We characterized these HF zebrafish mutants phenotypically and molecularly, identified the respective underlying genetic defects and verified the relevance in human heart failure [4–7]. Nevertheless, the molecular networks and common denominators of HF in these mutants are still unknown so far.

Findings from such model organisms can now be generalized via computational approaches by identifying important processes. This augments translational approaches which try to bridge the gap between experimental findings in varying model organisms and to transfer this knowledge to humans. They face the challenge of aligning the behavior of homologous genes and signaling pathways across species. The identification of stable marker signatures in binary or multi-categorial comparisons can identify the most specific markers for a phenotype of interest [8–10] and subsequently link it to a biological process. The generalizability of diagnostic models can be used to access the importance of a marker signature [11–13]. Nevertheless, in very high-dimensional settings (n ≫ m, where n is the dimensionality and m is the cardinality of a dataset) the possibility of reconstructing molecular dependencies in a poorly data-driven way might be limited due to the restricted amount of data. In this case, the training of diagnostic models might be supported by semantic domain knowledge [14,15] on the components of known high-level processes and in turn help to identify them. In this work, we analyze the weak contractility/heart failure phenotype of zebrafish with the help of semantic multi-classifier systems. This model type generates a high-level hypothesis on the underlying processes which is then transferred from one model organism (zebrafish) to another (Wistar rat).

2. Results and Discussion

2.1. Zebrafish

Weak contractility as a common phenotype of HF is known to be caused by many different genetic mutations [16,17]. Therefore, it can be seen as a diagnostic hypernym comprising a large plethora of genetic backgrounds which lead to a common phenomenon. On a gene expression level, the common structure among these genotypes might be revealed by a common gene signature (i.e., subset of genes) that allows for a highly accurate categorization of all subclasses [10]. It can be seen as a hypothesis on the underlying processes of HF. Interestingly, this analysis does not require identical gene expression levels for all genetic subclasses. Genotype-dependent differences might be taken into account by models that provide individual prototypes for each subclass.

Seven distinct N-ethyl-N-nitrosourea (ENU)-induced zebrafish mutants all displaying severely reduced contractile performance and finally a HF-like phenotype were subjected to RNA sequencing to define transcriptional mRNA profiles. Dead beat mutant embryos suffer from the progressive reduction of cardiac contractility due to a disturbed Vascular endothelial growth factor (VEGF)/Phospholipase C (PLC) γ1 signaling cascade and thereby altered intracellular calcium transients in cardiomyocytes [18]. Mutation of the α1C L-type calcium channel subunit (C-LTCC) leads to fibrillating atria and non-contractile ventricles in island beat mutant zebrafish embryos [19]. Furthermore, main squeeze and lost contact mutant zebrafish embryos develop a HF-like phenotype due to the loss of function of a novel component of the cardiac mechanical stretch sensor, Integrin-linked kinase [5,7]. Weak atrium zebrafish mutants display severe cardiac dysfunction due to mutation of atrial myosin heavy chain (myh6) [20], whereas carboxy-terminal truncation of cardiac essential myosin light chain-1 (cmlc1) leads to diminished cardiomyocyte contractility in homozygous mutant lazy susan zebrafish embryos [21]. Finally, we also analyzed tell-tale heart mutant zebrafish embryos which suffer from contractile dysfunction and a HF-like phenotype due to loss of cardiac myosin light chain 7 (myl7) [4].

In the following, we use semantic multi-classifier systems (S-MCS) for screening for such common gene signatures. These systems are guided by external domain knowledge in form of vocabularies of known gene signatures and processes. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were chosen for our experiments. To take into account effects of multiple genotypes of the heart failure phenotype, the one nearest neighbor classifier (1-NN) was used as a multi-centric base
classifier. The 1-NN was also used for non-semantic (data-driven) reference experiments. A summary of all experiments can be found in Table 1. They are conducted as 10 × 10 cross-validation (CV) experiments. Both S-MCS outperform the data-driven 1-NN by at least 17.0% accuracy.

Table 1. Results of the 10 × 10 cross-validation experiments (zebrafish). The average accuracy, sensitivity (mutation) and specificity (control) is reported for the semantic multi classifier system (S-MCS) and the 1-nearest neighbor (1-NN) classifier. Additionally, the five most frequently selected KEGG pathways and GO terms are shown (%). The table additionally provides results of experiments with vocabularies comprising 100 sets of randomly selected (with replacement) genes (cardinality per set: 15 or 20). Median average accuracy, sensitivity, and specificity together with interquartile range (IQR) are given.

| Cross-validation performance (10 × 10 cross-validation (CV)): | Accuracy (Acc): | Sensitivity (Sens): | Specificity (Spec): |
|-------------------------------------------------------------|-----------------|------------------|------------------|
| S-MCS (GO)                                                  | 95.2%           | 95.8%            | 94.6%            |
| S-MCS (KEGG)                                                | 91.5%           | 87.5%            | 95.4%            |
| 1-NN (all genes)                                            | 74.8%           | 79.2%            | 70.4%            |

| Most Frequent GO Terms (%):                                  |                  |                  |                  |
|--------------------------------------------------------------|-----------------|-----------------|-----------------|
| 1. RNA Polymerase II Transcription Factor Binding             | 55%             |                  |                  |
| 2. Transaminase Activity                                     | 42%             |                  |                  |
| 3. Myoblast Differentiation                                   | 23%             |                  |                  |
| 4. Cellular Biogenic Amine Metabolic Process                  | 19%             |                  |                  |
| 5. Hormone Activity                                          | 16%             |                  |                  |

| Most Frequent KEGG Pathways (%):                             |                  |                  |                  |
|--------------------------------------------------------------|-----------------|-----------------|-----------------|
| 1. Arginine biosynthesis                                     | 75%             |                  |                  |
| 2. Biosynthesis of unsaturated fatty acids                    | 55%             |                  |                  |
| 3. Fatty acid elongation                                      | 37%             |                  |                  |
| 4. Alanine, aspartate and glutamate metabolism                | 29%             |                  |                  |
| 5. Cytokine-cytokine receptor interaction                    | 29%             |                  |                  |

| Random Vocabularies (100 repetitions, 10 × 10 cross-validation (CV)): | Acc: | Sens: | Spec: |
|-----------------------------------------------------------------------|------|-------|-------|
| S-MCS (100 × 15 rand. genes) median                                   | 91.6% | 91.7% | 92.9% |
|                          IQR [88.8–94.6%]                           | [87.1–94.6%] | [88.3–95.5%]   |
| S-MCS (100 × 20 rand. genes) median                                   | 92.6% | 91.3% | 93.5% |
|                          IQR [89.1–95.4%]                           | [87.8–95.0%] | [91.2–96.7%]   |
| 1-NN (100 rand. genes) median                                         | 78.5% | 78.5% | 78.8% |
|                          IQR [67.2–86.1%]                           | [66.6–87.5%] | [70.0–87.2%]   |

The highest classification accuracy was achieved by the S-MCS based on selected GO terms. Mutants and controls were separated with an accuracy of 95.2%. For the mutant class, a sensitivity of 95.8% was reached. The corresponding specificity was 94.6%. Within the top ranking of the five most frequently selected terms already a steep descent in frequency can be observed (39% loss). The two most frequently selected terms were selected in over 50% of all experiments. RNA polymerase II transcription factor binding achieved a frequency of 55% followed by transaminase activity with a frequency of 42%. The remaining three terms achieve frequencies of 23% (myoblast differentiation), 19% (cellular biogenic amine metabolic process) and 16% (hormone activity). The gene expression levels of the top two GO terms can be found in Figure 1.

The term RNA polymerase II transcription factor binding is represented by 21 markers. RNA polymerase II (pol II) is one of three RNA polymerases in eukaryotic cells and responsible for the production of mRNA as well as most microRNA and small nuclear RNA (snRNA). After transcription factors and mediators have been recruited and bound to pol II transcription is initiated at the promoter of the gene. Correct regulation and function of pol II activity is necessary for regular tissue homeostasis. Loss of certain transcription factors such as TEADs (TEF family transcription factors), GATA and FOG (fried of GATA) [22–28] result in pathophysiologic phenotypes [29] as they are necessary for normal heart development (link to another term found: myoblast differentiation). TEADs
directly interact with pol II and activate and regulate the expression of several genes involved in cardiac muscle contraction (e.g., MYH6 and MYH7, aka myosin heavy chains a and β [22], SERCA2, aka sarcoendoplasmic reticulum Ca\(^{2+}\)-ATPase 2a [24], and others [23]). Loss or overexpression of TEAD1 leads to several phenotypes associated with HF such as fibrosis, contractile dysfunction, hypertrophy, and conduction defects [22–24]. DNA binding protein GATA4 and associated proteins (e.g., MEF2a, aka myocyte-specific enhancer factor 2a, and FOG) are involved in cardiac development and are upregulated in cardiac hypertrophy [25–28,30,31] (again tying in with the term myoblast differentiation). Loss of these proteins or their interactions results in phenotypes of cardiac failure including fibrosis, ventricular dilation, contractile dysfunction, hypoxia, and hypertrophy [25–28,30]. Many more transcription factors such as ankyrin, NELF (negative elongation factor) and SRF (serum response factor) are also involved in maintaining correct cardiac function, and their deregulation results in HF [29,32–34]. All in all, this shows that correct function of transcription factors and transcription itself is necessary for healthy heart function.

The RNA-Seq profiles represent the term transaminase activity by 25 markers. Transaminases are enzymes which catalyze a reaction to transfer an amine group from an amino acid to a keto acid, where the amine group replaces the keto group. In dilated left ventricles (due to pressure overload) elevated levels of tauine, glutamine, glutamate, aspartate, and alanine have been found compared to undilated heart tissue [35]. This may be due to increased glutamine and alanine metabolism to compensate for anaerobic metabolic stress and energy deficiency in failing hearts [35]. Similarly, ischemic hearts take up more glutamine and aspartate while producing increased levels of alanine in anaerobic reactions to feed the citric cycle (through transamination) [36]. This provides additional

**Figure 1.** Heatmap of the two most frequently selected GO terms (RNA polymerase II transcription factor binding (55.0%) and transaminase activity (42.0%)) in zebrafish. The figure provides the gene expression levels of the genes these terms comprise. Within each term, the genes are ordered according their Spearman correlation to the class label (mutant/control). Each gene was z-transformed individually. Within each class, hierarchical clustering (average linkage) was used to organize the samples.
substrates for oxidation and antioxidants in times of stress [36,37]. In this respect, infusion of L-glutamate after ischemic infarction seems to improve cardiac metabolism and reduce infarction size and further tissue damage [38]. This all ties in with a similar pathway found in our analyses of KEGG pathways—Alanine, aspartate and glutamate metabolism—reinforcing the importance of amino acid metabolism in the energy metabolism and thus contractility of the heart.

The semantic multi-classifier system based on the KEGG pathway collection achieved an accuracy of 91.5%. The mutant class was detected with sensitivity of 87.5% and a specificity of 95.4%. The five most frequently selected terms are arginine biosynthesis (75%) and biosynthesis of unsaturated fatty acids (55%) followed by fatty acid elongation (37%), alanine, aspartate, and glutamate metabolism (29%) and cytokine-cytokine receptor interaction (29%). Figure 2 provides the gene expression levels of the top 2 terms.

Arginine biosynthesis is represented by 23 markers. Most arginine is synthesized in the kidneys; however, most cells can synthesize arginine from citrulline [39]. By transaminating glutamine, proline, and ornithine nearly every organ can produce arginine (via citrulline) though this is energetically costly [39] (see transaminase activity above). In the cardiovascular system, arginine availability correlates with endothelial function and cardiac contractility [40,41] since arginine is a necessary substrate for nitric oxide (NO) synthesis [41–43]. Nitric oxide synthetase 2 is only expressed in cardiac tissue and ornithine nearly every organ can produce arginine (via citrulline) though this is energetically costly [39].

Figure 2. Heatmap of the two most frequently selected KEGG terms arginine biosynthesis (75%) and biosynthesis of unsaturated fatty acids (55%) in zebrafish. The figure provides the gene expression levels of the genes these terms comprise. Within each term, the genes are ordered according their Spearman correlation to the class label (mutant/control). Each gene was z-transformed individually. Within each class, hierarchical clustering (average linkage) was used to organize the samples.
The RNA-Seq profiles comprise 24 markers for the term **Biosynthesis of unsaturated fatty acids**. Most of the hearts energy is derived from fatty acid (FA) oxidation [46,47]. Usually, FAs are converted into long-chain acyl-CoA esters, transported into the mitochondria and β-oxidized into acetyl-CoA for the citric cycle [46]. During HF, however, the heart increases glucose metabolism while decreasing FA oxidation leading to reduced energy output and contractility [47]. On the other hand, defects in enzymes of mitochondrial FA synthesis result in a phenotype closely resembling failing or failed heart with dysfunctional mitochondria [48]. Defects in other enzymes of FA synthesis also lead to HF phenotypes with reduced contractility [49,50]. During aging, some unsaturated FAs in mitochondrial cardiolipin are replaced with polyunsaturated FAs which is associated with heart dysfunction and impaired contractility [51]. Overall, this leads to the conclusion that the metabolism of unsaturated FAs plays an important role in cardiac function.

### 2.2. Cross-Species Experiment: Wistar Rats

To validate and prove the cardiac relevance of these findings, we next analyzed transcriptional profiles derived from a cellular rat cardiomyocyte hypertrophy model and compared these cardiomyocyte-specific profiles to our whole zebrafish data.

Originally aiming for the identification of new mechanosensitive genes in cardiomyocyte hypertrophy and cardiac remodeling, we subjected neonatal rat ventricular cardiomyocytes (NRVCMs) to cyclic biomechanical stretch for 2, 6, or 24 h (116% at 1 Hz) respectively. RNA isolated from these cells was then analyzed using Agilent’s (Santa Clara, CA, USA) standard Rattus norvegicus 8x60K_60mer mRNA microarrays. The heat map (Figure 3) shows leave one out CV experiments with semantic 1-NN classifiers. Gene expression profiles were thereby restricted to the most frequently selected terms of the *Danio rerio* experiments. As a negative control we also analyzed the prediction based on randomly selected gene sets. Using 1000 repeats of 100 randomly selected genes from the Wistar rat we achieved a mean accuracy of 51.7% (interquartile range, IQR: [41.7–66.7%]).

**Figure 3.** Leave one out cross-validation on rat data using the terms selected in the zebrafish experiments. Additionally, an experiment based on the whole gene expression profiles is shown. Each row indicates a separate experiment. The cell color denotes the predicted stretch time of a sample. The axis on the right gives the overall accuracies (%) of the experiments.

Biomechanical stretch is a typical inductor of cardiac hypertrophy [52], which in turn represents an integral part of a process termed cardiac remodeling. In the later phases of cardiac remodeling and
in addition to hypertrophy, fibrosis and apoptotic cell death take stage and finally lead to contractile
dysfunction [53]. Thus, the cardiomyocyte stretch model used here represents an excellent in vitro
model to resemble cardiomyocyte hypertrophy and early stages of cardiac remodeling. Interestingly,
the high-level processes revealed by our experiments could also be applied to classify this stretch
model of rats.

3. Conclusions

The major contribution of this work is a large-scale analysis of weak contractility phenotypes
observable in the model organism zebrafish. Overall 48 RNA-Seq profiles of seven weak contractility/
heart failure genotypes were analyzed. Our knowledge-based approach, a semantic multi-classifier
system, allows for the construction of diagnostic models, which can directly be interpreted in high-level
terms chosen from a predefined and accepted vocabulary. In our case, the collections of KEGG
pathways and GO terms are chosen.

In our study, we use both RNA-Seq and Microarrays in our transfer experiment from zebrafish to
rat data. Both platforms can determine gene expression levels, though RNA-Seq is better at quantifying
absolute expression levels as well as levels of very low and very high expressing genes [54–57].
Other than that, both platforms produce comparable results: they are highly reproducible and
comparable [58–60] and they agree on fold-change direction and significance values [57,61] (though
RNA-Seq usually finds more significantly differentially expressed genes [61]). Usually, microarrays are
the weaker platform when trying to find differentially expressed genes and determining expression
levels. However, RNA-Seq has its own inherent problems. RNA degradation is an issue with both
platforms; however, sample preparation for RNA-Seq is more complex the risk for introducing a
bias through RNA degradation is higher [55]. In addition, while RNA-Seq has better coverage of all
genes (since it is not dependent on probes) it has its own problems with uneven coverage, limiting
of sequencing depth and matching genes to the reference sequence [55,57]. Overall, both platforms
have their application-specific advantages and drawbacks. For our experimental setup, the arguments
usually used in favor of RNA-Seq (better coverage, finding of non-annotated genes, splice variants
and low-expressing genes) do not necessarily apply, since we can only use genes which are already
annotated and included in a term of the KEGG or GO databases. Since we generate our model on
RNA-Seq data and then apply it to microarray data the fine-grained nature of the expression levels is
already included in the model. Only coverage might be a problem when transferring the model to
microarray data: since microarrays can only evaluate genes for which they have probes, some genes
included in the model may not appear in the microarray data. Due to this, some discrepancies may
arise when comparing results. This one of the reasons for making the information transfer on a process
level. However, the key genes of each pathway are known and probed, so discrepancies should be
kept to a minimum. In addition, since we aim for transferability not only between platforms but also
between species small discrepancies are expected and out model can clearly withstand them.

Our findings demonstrate the applicability of the terms identified in the lower vertebrate model
zebrafish to the mammalian model system rat. As already described, transcriptional profiles were
obtained from embryonic zebrafish at 3 days of age. At this stage cardiogenesis, particularly cardiac
maturation, is still ongoing although strong rhythmic and sequential contractions of the atrium and
the ventricle are well established. Cardiomyocytes isolated from neonatal rat hearts at P1-3 do not
represent fully matured adult cardiomyocytes as well, suggesting that both used model systems are
comparable, since their developmental time points and stages almost fully match. In future studies,
it will be interesting to compare our findings to adult heart failure models and test their transferability
and applicability.

As described before, RNA-Seq profiles were obtained using RNA samples prepared from whole
zebrafish embryos at 72 hpf. In contrast to the situation in mammalian cardiovascular disease model
systems such as mice, zebrafish embryos at 72 hpf which suffer from severe cardiovascular disorders
do usually not exhibit pronounced adverse secondary effects on development and function of other
organ systems since e.g., hypoxia is assumed to be only minimal due to the fact that oxygen supply is mostly supplied by passive diffusion from the surrounding water. Nevertheless, recent data derived from transcriptional profiling of the zebrafish mutant steif (Unc45b-deficiency) which suffers from severe striated muscle defects including cardiac contractile insufficiency displays the upregulation of genes involved in hypoxia-response [62]. These findings imply that there might be at least a transcriptional hypoxia-like response as a reflection of the cardiac defect, though it is not known if this also reflects cellular hypoxia in vivo. Kajimura and coworker found that hypoxic stress in the developing zebrafish embryo mainly results in embryonic growth retardation [63] which was not observed in the heart failure zebrafish mutants used in our study, suggesting that—if present at all—hypoxia-induced secondary effects are rather minimal here. Whether reduced cardiac contractile performance and compromised blood flow led to other secondary physiological changes which might impact the transcriptional profiles of our zebrafish mutants is yet unknown; however, we also did not see any evidence of such effects.

Nevertheless, cardiac tissue was only a small fraction of the entire tissue mass used for transcriptional profiling, insinuating that some of our zebrafish transcriptional findings might be only associated with non-cardiac tissues and therefore not applicable to HF. To overcome this limitation, bioinformatic evaluation of cardiac- or even cardiomyocyte-specific transcriptional profiles of our heart failure zebrafish mutants will be fundamental. These experiments are already planned for the near future. Additionally, to validate and prove the cardiac relevance of these whole-embryo findings, we also analyzed transcriptional profiles derived from a cellular rat cardiomyocyte hypertrophy model and compared these cardiomyocyte-specific profiles to our whole zebrafish data.

The most frequently selected terms of this analyses, RNA polymerase II transcription factor binding (55%, GO) and transaminase activity (42%, GO) as well as arginine biosynthesis (75%, KEGG) and biosynthesis of unsaturated FAs (55%, KEGG) fit well into the context of the weak contractility phenotype. Focusing on the high-level terms also allowed an easy transfer from the model organism Danio rerio to the model organism Wistar rat. From a statistical point of view, the selection frequency of the top GO terms and KEGG pathways must be seen as a rare event. They are the only high-level terms out of 152 KEGG pathways and 4354 GO terms with a selection frequency of at least 40%. For both vocabularies, the selection frequency drops to at most 16% within the corresponding top five lists.

In our zebrafish experiments, in comparison to their naive data-driven counterpart, all selection-based approaches improved the CV accuracies. This effect cannot be explained by random dimensionality or feature reduction on their own as shown by the experiments with the one nearest neighbor classifier. Guided selection processes are needed to identify discriminating features. In contrast to other approaches, our system is not focused on individual supportive markers. It also takes into account disadvantageous genes and therefore leads to an assessment of gene sets. While in general the proposed multi-classifier system can operate on random gene sets, the final model will clearly lack the interpretation of known pathways and analyzed gene interactions. Interpretability can only be achieved by incorporating existing domain knowledge in the analysis of complex datasets.

In terms of accuracy, both vocabularies led to comparable results. The semantic multi-classifier systems achieved at least 91.5% CV accuracy. Our study provides a high-level roadmap on the molecular processes on the weak contractility/heart failure phenotype in Danio rerio and its corroboration on Wistar rats. This cross-species integration paves the way for a deeper molecular investigation of the involved mechanisms.

4. Materials and Methods

4.1. Zebrafish Strains, Fractional Shortening Measurements, RNA Isolation and RNA Sequencing

All procedures and experiments in this study were carried out after appropriate institutional approvals (Tierforschungszentrum (TFZ) Ulm University, No. 0183), which conform to the EU Directive 2010/63/EU. Care and breeding of zebrafish (Danio rerio) was carried out as described
in Kustermann et al. [64]. Fractional shortening was determined by measuring the diameters of the ventricle at the end of contraction (systole) and relaxation (diastole) using the zebraFS software (http://www.benegfx.de) [65]. RNAs from seven different weak contractility/heart failure zebrafish mutant lines were extracted (25 embryos/sample) using the RNeasy Plus Mini Kit (Qiagen, Venlo, The Netherlands) at 72 hpf and subjected to RNA sequencing (Illumina HiSeq 2000, Core Facility Genomics, Ulm University, Germany). Samples were collected at 72 hpf since at this specific and early time point cardiac contractile dysfunction was nicely established in all lines without visibly affecting overall embryonic development and morphology.

Table 2 provides an overview on the collected dataset. Overall 48 samples of seven different weak contractility heart failure genotypes are available. The dataset splits into 24 pairs of observable mutant phenotypes and the corresponding controls. For each sample, an RNA-Seq profile of 31,953 measurements is recorded. A mutant was categorized as a member of weak contractility superclass if it demonstrated significantly reduced ventricular fractional shortening (FS) measurements compared to their wild-type siblings Figure 4; see also [4,5,18,21]):

**Table 2.** Overview of the analyzed dataset: The dataset comprises gene expression profiles of 48 whole-fish samples seven individual genotypes (rows) with a weak contractility. The genotypes are named according to their observable heartbeat. For each genotype, the number of samples (mutants(mut)/controls(crt)) is reported.

| No. | Genotype            | Samples (mut/crt) |
|-----|---------------------|-------------------|
| 1.  | dead beat (m582)    | (3/3)             |
| 2.  | island beat (m458)  | (6/6)             |
| 3.  | lazy susan (m647)   | (3/3)             |
| 4.  | lost contact (hu801)| (3/3)             |
| 5.  | main squeeze (m347) | (3/3)             |
| 6.  | tell-tale heart (m225)| (3/3)           |
| 7.  | weak atrium (m229)  | (3/3)             |
|     | summary             | (24/24)          |

**Figure 4.** Ventricular fraction shortening of weak contractility/heart failure genotypes (zebrafish). For all genotypes, the differences between mutants and controls were tested (n = 7, Wilcoxon-Rank-Sum tests, Bonferroni correction for multiple testing). Significance levels are indicated as *: p < 0.05, **: p < 0.01, ***: p < 0.001.

4.2. **Stretch Experiments in Neonatal Rat Ventricular Cardiomyocytes (NRVCMS)**

Neonatal rat ventricular cardiomyocytes (NRVCMS) were isolated, cultured, and biomechanically stretched as described previously [66]. In brief, NRVCM isolated from 1–3 days old Wistar rats using standard techniques were subjected to cyclic biomechanical stretch for 2, 6, or 24 h using the Flexcell FX-5000T-FLK system (Flexcell international, Dunn Labortechnik, Asbach, Germany). The cells, seeded in a density of 1.5 × 10^6/well, were stretched on collagen I-coated plates (Bioflex
plates, Flexcell international, Dunn Labortechnik) to an extend of 116% at 1 Hz. Non-stretched cells cultivated simultaneously on similarly prepared plates in the same incubator were used as controls. NRVCMS were harvested for RNA isolation using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions for use. Desoxyribonuclease I (DNase I) (Sigma-Aldrich, St. Louis, MO, USA) was used to digest potentially contaminating DNA. RNA was further analyzed using Agilent’s standard Rattus norvegicus 8x60K_60mer mRNA microarrays.

4.3. Classification

The weak contractility phenotype is analyzed in a binary classification experiment. We are interested in identifying a diagnostic model, a classifier, that allows the distinction between observed mutant phenotype \( y = 1 \) or control healthy phenotype \( y = 0 \) on a sample-wise level. In this context, each sample will be represented as a feature vector \( x = (x^{(1)}, \ldots, x^{(n)})^T \) and interpreted by the classifier. A diagnostic model will be seen as a function

\[
c : \mathcal{X} \rightarrow \mathcal{Y}
\]

mapping from the feature space \( \mathcal{X} \subseteq \mathbb{R}^n \) to the space of class labels \( \mathcal{Y} = \{0, 1\} \).

A classifier is adapted for a classification task in a data-driven initial learning phase

\[
l : \mathcal{C} \times \mathcal{T} \rightarrow c_T.
\]

Here, the final classification model \( c_T \) is chosen from a predefined concept class \( \mathcal{C} \) and adapted according to a set of labeled training examples \( \mathcal{T} = \{(x_i, y_i)\}_{i=1}^{|\mathcal{T}|} \). The subscript \( \tau \) will be omitted if not necessary. In a second step, the generalization performance of a trained classifier is estimated on an independent set of test or validation samples \( \mathcal{V} = \{(x_i', y_i')\}_{i=1}^{|\mathcal{V}|} \). For our experiments the empirical accuracy, sensitivity and specificity are chosen

\[
\text{acc}_\mathcal{V} = \frac{1}{|\mathcal{V}|} \sum_{(x_i, y_i) \in \mathcal{V}} \mathbb{1}_{c_T(x_i) = y_i}, \quad \text{sens}_\mathcal{V} = \frac{1}{|\mathcal{V}_1|} \sum_{(x_i, y_i) \in \mathcal{V}_1} \mathbb{1}_{c_T(x_i) = y_i}, \quad \text{spe}_\mathcal{V} = \frac{1}{|\mathcal{V}_0|} \sum_{(x_i, y_i) \in \mathcal{V}_0} \mathbb{1}_{c_T(x_i) = y_i}.
\]

Here, \( \mathcal{V}_1 \) and \( \mathcal{V}_0 \) denote a restriction of \( \mathcal{V} \) to the samples of class 1 or 0, respectively.

Each binary classification experiment is designed as a 10 \( \times \) 10 CV [67]. That is, the overall set of samples \( \mathcal{S} \) is partitioned into \( f = 10 \) folds \( \mathcal{F} \) of approximately equal size. They are used to generate independent pairs of training sets \( \mathcal{T}_i = \mathcal{S} \setminus \mathcal{F}_i \) and validation sets \( \mathcal{V}_i = \mathcal{F}_i \) for individual classification experiments. The \( i \)th classifier \( c_T \) is evaluated on \( \mathcal{V}_i \). The average accuracy, sensitivity and specificity are reported. To minimize sampling effects the mean values of \( r = 10 \) permutations of \( \mathcal{S} \) are provided. Experiments are performed with the R-package (www.r-project.org) TunePareto [68].

4.4. Semantic Multi-Classifier Systems (S-MCS)

We use Semantic Multi-Classifier Systems (S-MCS) for our experiments [14,15]. A S-MCS is a decision ensemble \( h : \mathcal{X} \rightarrow \mathcal{Y} \) that integrates the predictions of several base classifiers

\[
h(x) = u(c_1(x), \ldots, c_l(x)),
\]

where \( u : \mathcal{Y}_1 \times \ldots \times \mathcal{Y}_l \rightarrow \mathcal{Y} \) into one final prediction.

Each base classifier operates on an individual feature signature \( i = (i^{(1)}, \ldots, i^{(k)})^T \). It is restricted to a limited set of input signals \( x^{(i)} = (x^{(i^{(1)})}, \ldots, x^{(i^{(k)})})^T \). Each signature is coupled to a commonly accepted interpretation (term) and chosen from a predefined vocabulary \( i \in \mathcal{I} \) (Figure 5a). This selection process is based on an internal 3 \( \times \) 3 CV on the training set of the corresponding base classifier. The terms with the individual highest accuracies are chosen (Figure 5b). For our experiments we chose an unweighted majority vote as combining scheme and an ensemble size of three base
classifiers (Figure 5c). Semantic multi-classifier systems are trained for two vocabularies: the collection of KEGG pathways [69] and the GO terms [70].

Figure 5. Schematic drawing of a semantic multi-classifier system (S-MCS): The training of a S-MCS uses prior domain knowledge in form of a vocabulary of selected semantic terms (e.g., KEGG pathways of GO terms) for the analysis of incoming gene expression profiles. Each term is analyzed independently by a separate expert (classifier) which focuses on the chosen subset of measurements. The selection of these experts is aggregated via a fusion architecture, leading to a “mixture of experts”.

4.5. Nearest Neighbor Classification

As a base classifier the one nearest neighbor classifier (1-NN) is chosen [71]. The 1-NN is a member of the prototype-based classification $k$-NN algorithms which predict the class label of a query sample $v$ in the following way

$$ c(v) = \arg\max_{y \in \mathcal{Y}} \left| \{(x, y) \in \text{NN}_k(v, \mathcal{P})\} \right| . $$

(5)

Here, $\text{NN}_k(v, \mathcal{P})$ denotes the $k$ nearest neighborhood of $v$ in a set of prototypes $\mathcal{P} = \{(x_i, y_i)\}_{i=1}^{|\mathcal{P}|}$

$$ \text{NN}_k(v, \mathcal{P}) = \left\{ (x, y) \mid \text{rk}_{D_v} (d(v, x)) \leq k \right\} $$

(6)

and $D_v = \{d(v, x) \mid (x, y) \in \mathcal{P}\}$ the set of all pairwise Euclidian distances between $v$ and $\mathcal{P}$. The class label of $v$ is determined via a majority vote of the class labels of the selected candidates. In the case of 1-NN, $k = 1$ and $\mathcal{P} = \mathcal{T}$.

4.6. Pathways from Kyoto Encyclopedia of Genes and Genomes

The Kyoto Encyclopedia of Genes and Genomes comprises a collection of signaling pathways for a large spectrum of model organisms [69]. For Danio rerio 167 signaling pathways are available. For our experiments we restrict ourselves to those pathways that consist of at least 10 components (152 terms).

4.7. Gene Ontology Terms

The Gene Ontology is one of the largest attempts to construct an organized and standardized terminology for the categorization of gene products [70]. Its vocabulary is organized in a hierarchical ontology covering three different domains: biological processes, associated cellular components and molecular functions. Most of these terms are linked to manually curated gene lists. We again use those GO terms that comprise at least 10 genes in Danio rerio (4354 terms).

Author Contributions: L.L., L.S., H.A.K. analyzed data. S.J. and D.F. provided zebrafish and Wistar rat experiments. L.L., L.S., D.F., S.J., H.A.K. wrote the manuscript. W.R., D.F., S.J., H.A.K. conceptualised and supervised the project.
**Funding:** The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 602783, the German Research Foundation (DFG, SFB 1074 project Z1) to HAK, and the Federal Ministry of Education and Research (BMBF, e:Med, SYMBOL-HF; ID 01ZX1407A, CONFIRM, ID 01ZX1708C to HAK; JS and SYMBOL-HF, ID 01ZX1407C to DF).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Cook, C.; Cole, G.; Asaria, P.; Jabbour, R.; Francis, D.P. The annual global economic burden of heart failure. *Int. J. Cardiol.* 2014, 171, 368–376. [CrossRef] [PubMed]

2. Vigen, R.; Maddox, T.; Allen, L. Aging of the United States Population: Impact on Heart Failure. *Curr. Heart Failure Rep.* 2012, 9, 369–374. [CrossRef] [PubMed]

3. Stainier, D.Y.; Fouquet, B.; Chen, J.N.; Warren, K.S.; Weinstein, B.M.; Meiler, S.E.; Mohideen, M.A.; Neuhauß, S.C.; Solnica-Krezel, L.; Schier, A.F.; et al. Mutations affecting the formation and function of the cardiovascular system in the zebrafish embryo. *Development* 1996, 123, 285–292. [PubMed]

4. Rottbauer, W.; Wessels, G.; Dahme, T.; Just, S.; Tranø, N.; Hassel, D.; Burns, C.; Katus, H.; Fishman, M. Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. *Circ. Res.* 2006, 99, 323–331. [CrossRef] [PubMed]

5. Bendig, G.; Grimmler, M.; Huttner, I.; Wessels, G.; Dahme, T.; Just, S.; Tranø, N.; Katus, H.; Fishman, M.; Rottbauer, W. Integrin-linked kinase, a novel component of the cardiac mechanical stretch sensor, controls contractility in the zebrafish heart. *Genes Dev.* 2006, 20, 2361–2372. [CrossRef] [PubMed]

6. Meder, B.; Huttner, I.; Sedaghat-Hamedani, F.; Just, S.; Dahme, T.; Frese, K.; Vogel, B.; Köhler, D.; Kloos, W.; Rudloff, J.; et al. PINCH proteins regulate cardiac contractility by modulating integrin-linked kinase-protein kinase B signaling. *Mol. Cell. Biol.* 2011, 31, 3424–3435. [CrossRef] [PubMed]

7. Knöll, R.; Postel, R.; Wang, J.; Krätzner, R.; Hennecke, G.; Vacaru, A.; Vakeel, P.; Schubert, C.; Murthy, K.; Rana, B.; et al. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. *Circulation* 2007, 116, 515–525. [CrossRef]

8. Lausser, L.; Müssel, C.; Kestler, H.A. Measuring and Visualizing the Stability of Biomarker Selection Techniques. *Comput. Stat.* 2013, 28, 51–65. [CrossRef]

9. Schirra, L.R.; Lausser, L.; Kestler, H.A. Selection Stability as a Means of Biomarker Discovery in Classification. In *Analysis of Large and Complex Data*; Wilhelm, A.F.X., Kestler, H.A., Eds.; Studies in Classification, Data Analysis, and Knowledge Organization; Springer: Cham, Switzerland, 2016; pp. 79–89.

10. Lausser, L.; Szekely, R.; Schirra, L.R.; Kestler, H.A. The Influence of Multi-class Feature Selection on the Prediction of Diagnostic Phenotypes. *Neural Process. Lett.* 2018, 48, 863–880. [CrossRef]

11. Gress, T.M.; Lausser, L.; Schirra, L.R.; Ortmüller, L.; Diels, R.; Kong, B.; Michalski, C.W.; Hackert, T.; Strobel, O.; Giese, N.A.; et al. Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material. * Oncotarget* 2017, 8, 108223–1082370. [CrossRef] [PubMed]

12. Hesse, R.; Lausser, L.; Gumpert, P.; Schmid, F.; Wahler, A.; Schnack, C.; Kroeker, K.S.; Otto, M.; Tumani, H.; Kestler, H.A.; et al. Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. *Alzheimer’s Res. Therapy* 2017, 9, 17. [CrossRef] [PubMed]

13. Völkel, G.; Lausser, L.; Schmid, F.; Kraus, J.M.; Kestler, H.A. Sputnik: Ad hoc distributed computation. *Bioinformatics* 2015, 31, 1298–1301. [CrossRef] [PubMed]

14. Lausser, L.; Schmid, F.; Platzer, M.; Sillanpää, M.J.; Kestler, H.A. Semantic Multi-classifier Systems for the Analysis of Gene Expression Profiles. *Arch. Data Sci. Ser. A (Online First)* 2016, 1, 157–176.

15. Taudien, S.; Lausser, L.; Giamarellos-Bourboulis, E.J.; Sponholz, C.; Schöneweck, F.; Felder, M.; Schirra, L.R.; Schmid, F.; Gogos, C.; Groth, S.; et al. Genetic Factors of the Disease Course After Sepsis: Rare Deleterious Variants Are Predictive. *EBioMedicine* 2016, 12, 227–238. [CrossRef] [PubMed]

16. Skrzynia, C.; Berg, J.S.; Willis, M.S.; Jensen, B.C. Genetics and Heart Failure: A Concise Guide for the Clinician. *Curr. Cardiol. Rev.* 2011, 11, 10–17. [CrossRef]

17. Morita, H.; Seidman, J.; Seidman, C.E. Genetic causes of human heart failure. *J. Clin. Investig.* 2005, 115, 518–526. [CrossRef] [PubMed]
18. Rottbauer, W.; Just, S.; Wessels, G.; Tran, N.; Most, P.; Katus, H.; Fishman, M. VEGF–PLCγ1 pathway controls cardiac contractility in the embryonic heart. *Genes Dev.* 2005, 19, 1624–1634. [CrossRef] [PubMed]
19. Rottbauer, W.; Baker, K.; Wo, Z.; Mohideen, M.A.P.; Cantiello, H.F.; Fishman, M.C. Growth and Function of the Embryonic Heart Depend upon the Cardiac-Specific t-Type Calcium Channel α1 Subunit. *Dev. Cell* 2001, 1, 265–275. [CrossRef]
20. Berdougo, E.; Coleman, H.; Lee, D.H.; Stainier, D.Y.R.; Yelon, D. Mutation of weak atrium/atrial myosin heavy chain disrupts atrial function and influences ventricular morphogenesis in zebrafish. *Development* 2003, 130, 6121–6129. [CrossRef]
21. Meder, B.; Laufer, C.; Hassel, D.; Just, S.; Marquart, S.; Vogel, B.; Hess, A.; Fishman, M.; Katus, H.; Rottbauer, W. A single serine in the carboxyl terminus of cardiac essential myosin light chain-1 controls cardiomyocyte contractility in vivo. *Circ. Res.* 2009, 104, 650–659. [CrossRef]
22. Iwaki, H.; Sasaki, S.; Matsushita, A.; Ohba, K.; Matsunaga, H.; Misawa, H.; Oki, Y.; Ishizuka, K.; Nakamura, H.; Suda, T. Essential Role of TEA Domain Transcription Factors in the Negative Regulation of the MYH7 Gene by Thyroid Hormone and Its Receptors. *PLos ONE* 2014, 9, e88610. [CrossRef] [PubMed]
23. Kohli, S.; Ahuja, S.; Rani, W. Transcription Factors in Heart: Promising Therapeutic Targets in Cardiac Hypertrophy. *Curr. Cardiol. Rev.* 2011, 7, 262–271. [CrossRef] [PubMed]
24. Liu, R.; Lee, J.; Kim, B.S.; Wang, Q.; Buxton, S.K.; Balasubramanyam, N.; Kim, J.J.; Dong, J.; Zhang, A.; Li, S.; et al. Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. *JCI Insight* 2017, 2, e93343. [CrossRef] [PubMed]
25. Fosset, N.; Zhang, Q.; Gajewski, K.; Choi, C.Y.; Kim, Y.; Schulz, R.A. The multitype zinc-finger protein U-shaped functions in heart cell specification in the Drosophila embryo. *Proc. Natl. Acad. Sci. USA* 2000, 97, 7348–7353. [CrossRef]
26. Zhou, B.; Ma, Q.; Kong, S.W.; Hu, Y.; Campbell, P.H.; McGowan, F.X.; Ackerman, K.G.; Wu, B.; Bin, Z.; Tevosian, S.G.; et al. Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart. *J. Clin. Investig.* 2009, 119, 1462–1476. [CrossRef] [PubMed]
27. Pikkarainen, S.; Tokola, H.; Kerkelä, R.; Ruskoaho, H. GATA transcription factors in the developing and adult heart. *Cardiovasc. Res.* 2004, 63, 196–207. [CrossRef] [PubMed]
28. Suzuki, Y.J. Cell signaling pathways for the regulation of GATA4 transcription factor: Implications for cell growth and apoptosis. *Cell. Signal.* 2011, 23, 1094–1099. [CrossRef] [PubMed]
29. Pan, H.; Qin, K.; Guo, Z.; Ma, Y.; April, C.; Gao, X.; Andrews, T.G.; Bokov, A.; Zhang, J.; Chen, Y.; et al. Negative Elongation Factor Controls Energy Homeostasis in Cardiomyocytes. *Cell Rep.* 2014, 7, 79–85. [CrossRef] [PubMed]
30. Wang, Y.X.; Qian, L.X.; Yu, Z.; Jiang, Q.; Dong, Y.; Liu, X.F.; Yang, X.Y.; Zhong, T.P.; Song, H.Y. Requirements of myocyte-specific enhancer factor 2A in zebrafish cardiac contractility. *FEBS Lett.* 2005, 579, 4843–4850. [CrossRef]
31. Yilbas, A.; Hamilton, A.; Wang, Y.; Mach, H.; Lacroix, N.; Davis, D.; Chen, J.; Li, Q. Activation of GATA4 gene expression at the early stage of cardiac specification. *Front. Chem.* 2014, 2, 12. [CrossRef]
32. Bang, M.L.; Gu, Y.; Dalton, N.D.; Peterson, K.L.; Chien, K.R.; Chen, J. The Muscle Ankyrin Repeat Proteins CARP, Ankrd2, and DARP Are Not Essential for Normal Cardiac Development and Function at Basal Conditions and in Response to Pressure Overload. *PLos ONE* 2014, 9, e93638. [CrossRef]
33. Miano, J.M.; Long, X.; Fujitawara, K. Serum response factor: Master regulator of the actin cytoskeleton and contractile apparatus. *Am. J. Physiol. Cell Physiol.* 2007, 292, C270–C81. [CrossRef] [PubMed]
34. Fowler, T.; Sen, R.; Roy, A.L. Regulation of Primary Response Genes. *Mol. Cell* 2011, 44, 348–360. [CrossRef] [PubMed]
35. Venturini, A.; Ascione, R.; Lin, H.; Polese, E.; Angelini, G.D.; Suleiman, M.S. The importance of myocardial amino acids during ischemia and reperfusion in dilated left ventricle of patients with degenerative mitral valve disease. *Mol. Cell. Biochem.* 2009, 330. [CrossRef] [PubMed]
36. Drake, K.J.; Sidorov, V.Y.; McGinness, O.P.; Wasserman, D.H.; Wikswo, J.P. Amino acids as metabolic substrates during cardiac ischemia. *Exp. Biol. Med.* 2012, 237, 1369–1378. [CrossRef] [PubMed]
37. Williams, H.; King, N.; Griffiths, E.J.; Suleiman, M.S. Glutamate-loading Stimulates Metabolic Flux and Improves Cell Recovery Following Chemical Hypoxia in Isolated Cardiomyocyte. *J. Mol. Cell. Cardiol.* 2001, 33, 2109–2119. [CrossRef] [PubMed]
43. Steppan, J.; Ryoo, S.; Schuleri, K.H.; Gregg, C.; Hasan, R.K.; White, A.R.; Bugaj, L.J.; Khan, M.; Santhanam, L.; Nyhan, D.; et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Proc. Natl. Acad. Sci. USA 2002, 103, 4759–4764. [CrossRef] [PubMed]

44. Ziolo, M.T.; Kohr, M.J.; Wang, H. Nitric oxide signaling and the regulation of myocardial function. J. Mol. Cell. Cardiol. 2008, 45, 625–632. [CrossRef] [PubMed]

45. Heidorn, M.; Frodermann, T.; Bönig, A.; Schreckenberg, R.; Schlüter, K.D. Citrulline Improves Early Post-Ischemic Recovery or Rat Hearts In Vitro by Shifting Arginine Metabolism From Polyamine to Nitric Oxide Formation. Clin. Med. Insights Cardiol. 2018, 12. [CrossRef] [PubMed]

46. Dyck, J.R.B.; Lopaschuk, G.D. Malonyl CoA Control of Fatty Acid Oxidation in the Ischemic Heart. J. Mol. Cell. Cardiol. 2002, 34, 1099–1109. [CrossRef] [PubMed]

47. Wende, A.R.; Brahma, M.K.; McGinnis, G.R.; Young, M.E. Metabolic Origins of Heart Failure. JACC Basic Transl. Sci. 2017, 2, 297–310. [CrossRef] [PubMed]

48. Chen, Z.; Leskinen, H.; Liimatta, E.; Sormunen, R.T.; Miinalainen, I.J.; Hassinen, I.E.; Hiltunen, J.K. Myocardial Overexpression of Mecr, a Gene of Mitochondrial FAS II Leads to Cardiac Dysfunction in Mouse. PLoS ONE 2009, 4, e5589. [CrossRef]

49. Guertl, B.; Noehammer, C.; Hoeffler, G. Metabolic cardiomyopathies. Int. J. Exp. Pathol. 2000, 81, 349–372. [CrossRef]

50. Blondelle, J.; Ohno, Y.; Gache, V.; Guyot, S.; Storck, S.; Blanchard-Gutton, N.; Barthélémy, I.; Walmsley, G.; Rahier, A.; Gadim, S.; et al. HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth. J. Mol. Cell Biol. 2015, 7, 429–440. [CrossRef]

51. Mulligan, C.M.; Le, C.H.; de Mooy, A.B.; Nelson, C.B.; Chicco, A.J. Inhibition of Delta-6 Desaturase Reverses Cardioli pin Remodeling and Prevents Contractile Dysfunction in the Aged Mouse Heart Without Altering Mitochondrial Respiratory Function. J. Gerontol. Ser. A 2014, 69, 799–809. [CrossRef]

52. Frank, D.; Kuhn, C.; Brors, B.; Hanselmann, C.; Lüdde, M.; Katus, H.A.; Frey, N. Gene expression pattern in biomechanically stretched cardiomyocytes: Evidence for a stretch-specific gene program. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2008, 1781, 309–318. [CrossRef] [PubMed]

53. Hill, J.A.; Olson, E.N. Cardiac Plasticity. N. Engl. J. Med. 2008, 358, 1370–1380. [CrossRef] [PubMed]

54. Sirbu, A.; Kerr, G.; Crane, M.; Ruskin, H.J. RNA-Seq vs Dual- and Single-Channel Microarray Data: Sensitivity Analysis for Differential Expression and Clustering. PLoS ONE 2012, 7, e50986. [CrossRef] [PubMed]

55. Zhao, S.; Fung-Leung, W.P.; Bittner, A.; Ngo, K.; Liu, X. Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells. PLoS ONE 2014, 9, e78644. [CrossRef] [PubMed]

56. Lowe, R.; Shirley, N.; Beaclkey, M.; Dolan, S.; Shafee, T. Transcriptomics technologies. PLoS ONE Comput. Biol. 2017, 13, e2005457. [CrossRef] [PubMed]

57. Rai, M.F.; Tycksen, E.D.; Sandell, L.J.; Brophy, R.H. Advantages of RNA-seq compared to RNA microarrays for transcriptome profiling of anterior cruciate ligament tears. J. Orthop. Res. 2017, 36, 484–497. [CrossRef] [PubMed]

58. Marioni, J.C.; Mason, C.E.; Mane, S.M.; Stephens, M.; Gilad, Y. RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008, 18, 1509–1517. [CrossRef] [PubMed]
59. Nookaeq, I.; Papini, M.; Pornputtapong, N.; Scalciati, G.; Fagerberg, L.; Uhlen, M.; Nielsen, J. A comprehensive comparison of RNA-Seq-based transcriptome analysis from reads to differential gene expression and cross-comparison with microarrays: A case study in *Saccharomyces cerevisiae*. *Nucleic Acids Res.* 2012, 40, 10084–10097. [CrossRef]

60. Chen, L.; Sun, F.; Yang, X.; Jin, Y.; Shi, M.; Wang, L.; Shi, Y.; Zhan, C.; Wang, Q. Correlation between RNA-Seq and microarrays results using TCGA data. *Gene* 2017, 628, 200–204. [CrossRef]

61. Bottomly, D.; Walter, N.A.R.; Hunter, J.E.; Darakjian, P.; Kawane, S.; Buck, K.J.; Searles, R.P.; Mooney, M.; McWeeny, S.K.; Fitzemann, R. Evaluating Gene Expression in C57BL/6J and DBA/2J Mouse Striatum Using RNA-Seq and Microarrays. *PLoS ONE* 2011, 6, e17820. [CrossRef]

62. Etard, C.; Armant, O.; Roostalu, U.; Gourain, V.; Ferg, M.; Strähle, U. Loss of function of myosin chaperones triggers Hsf1-mediated transcriptional response in skeletal muscle cells. *Genome Biol.* 2015, 16, 267. [CrossRef] [PubMed]

63. Kajimura, S.; Aida, K.; Duan, C. Insulin-like growth factor-binding protein-1 (IGFBP-1) mediates hypoxia-induced embryonic growth and developmental retardation. *Proc. Natl. Acad. Sci. USA* 2005, 102, 1240–1245. [CrossRef] [PubMed]

64. Kustermann, M.; Manta, L.; Paone, C.; Kustermann, J.; Lausser, L.; Wiesner, C.; Eichinger, L.; Clemen, C.; Schröder, R.; Kestler, H.; et al. Loss of the novel Vcp (valosin containing protein) interactor Washc4 interferes with autophagy-mediated proteostasis in striated muscle and leads to myopathy in vivo. *Autophagy* 2018, 14, 1911–1927. [CrossRef] [PubMed]

65. Hirth, S.; Bühler, A.; Bührdel, J.; Rudeck, S.; Dahme, T.; Rottbauer, W.; Just, S. Paxillin and Focal Adhesion Kinase (FAK) Regulate Cardiac Contractility in the Zebrafish Heart. *PLoS ONE* 2016, 11, e0150323. [CrossRef] [PubMed]

66. Rangrez, A.Y.; Pott, J.; Kluge, A.; Frauen, R.; Stiebeling, K.; Hoppe, P.; Sossalla, S.; Frey, N.; Frank, D. Myeloid leukemia factor-1 is a novel modulator of neonatal rat cardiomyocyte proliferation. *Biochim. Biophys. Acta (BBA) Mol. Cell Res.* 2017, 1864, 634–644. [CrossRef] [PubMed]

67. Japkowicz, N.; Shah, M. Evaluating Learning Algorithms: A Classification Perspective; Cambridge University Press: New York, NY, USA, 2011.

68. Müssel, C.; Lausser, L.; Maucher, M.; Kestler, H.A. Multi-objective Parameter Selection for Classifiers. *J. Stat. Softw.* 2012, 46, 1–27. [CrossRef]

69. Kanehisa, M.; Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* 2000, 28, 27–30. [CrossRef] [PubMed]

70. Ashburner, M.; Ball, C.; Blake, J.; Botstein, D.; Butler, H.; Cherry, J.; Davis, A.; Dolinski, K.; Dwight, S.; Eppig, J.; et al. Gene Ontology: Tool for the unification of biology. *Nat. Genet.* 2000, 25, 25–29. [CrossRef] [PubMed]

71. Fix, E.; Hodges, J.L. Discriminatory Analysis: Nonparametric Discrimination: Consistency Properties; Technical Report Project 21-49-004, Report Number 4; USAF School of Aviation Medicine, Randolf Field: Universal City, TX, USA, 1951.

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).